Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRI tracks healthcare trends

This article was originally published in The Tan Sheet

Executive Summary

Information Resources, Inc. will roll out a 34,000-plus consumer panel to track and measure consumer purchases of pharmaceuticals. RxPulse "will allow clients to monitor Rx and OTC drug usage across key segments, including ailments treated, consumer attributes and channel purchasing, for both conventional retail and online buying," IRI says June 14. Panel is first phase of what IRI terms a "suite of services for the pharmaceutical and health care markets." Market research firm also is conducting surveys to examine consumer purchase habits related to Rx, OTC drugs using InfoScan retail scanner data. IRI's announcement comes shortly after ACNielsen launched its Homescan Rx/OTC Consumer Panel, which will involve roughly 24,000 people (1"The Tan Sheet" June 3, 2002, p. 14)...

You may also be interested in...



Rx-To-OTC Consumer Purchase Trends To Be Tracked By ACNielsen

ACNielsen's U.S. Homescan Rx/OTC Consumer Panel will help the pharmaceutical industry monitor consumers' purchasing trends with regard to new switch drugs, the market research firm contends

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS094180

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel